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Introduction 
The acute phase protein response is part of a non-specific and complex host response to 
inflammation.  It occurs shortly after tissue injury and may be induced by a range of different 
causes, including infectious, inflammatory, neoplastic, traumatic or immunological disease.  
It is mediated by pro-inflammatory cytokines such as interleukin-1 (IL-1), tumour necrosis 
factor-alpha (TNFα) and interleukin 6 (IL-6) (Dinarello 1984, Heinrich and others 1990, 
Sheahan and others 2011) and is stimulated by the disease process (Murata and others 
2004, Peterson and others 2004, Ceron and others 2005).  The acute phase protein 
response is a critical part of the early response to insult or injury, and plays an important role 
in survival of the host during these initial stages. 
Acute phase proteins (APP) demonstrate major, moderate and minor response levels, and 
these vary between species (Eckersall and Bell 2010).  An APP with a major response is 
one that has a low concentration in healthy animals, but will show a dramatic rise (100-1000-
fold) on stimulation with a peak between 24-48 hours and then a rapid decline.  A moderate 
response APP will increase 5-10 fold following stimulation, can take 48-72 hours to peak and 
will decrease more slowly.  A minor response APP will increase only slowly, and only up to 
twice it’s resting level.  In dogs, major response APPs include C-reactive protein (CRP) and 
serum amyloid A (SAA), while moderate responders include alpha-1 acid glycoprotein (AGP) 
and haptoglobin (Hp).  Acute phase proteins can also be divided into positive and negative 
proteins.  The positive APPs (Hp, CRP, caeruloplasmin, SAA, AGP, fibrinogen) increase in 
response to release of pro-inflammatory cytokines such as IL-1, IL-6 TNF-alpha, while the 
negative APPs (albumin, transferrin) decrease in response to inflammation (Ceron and 
others 2005). 
Although it has been conventionally believed that APPs were exclusively hepatocyte derived, 
there is now increasing evidence to support extra-hepatic generation in neoplastic and other 
disease states.  In people, CRP has been shown to be of value in identifying metastatic 
disease from primary renal tumours (Ramankulov and others 2008) as well as showing 
promise for monitoring rejection of renal transplants (Jabs and others 2003).  Serum CRP 
correlates with survival in colorectal cancer (Chung and Chang 2003, Gutfeld and others 
2006) and oesophageal squamous cell carcinoma (Nozoe and others 2002) while SAA 
concentrations have been shown to correlate with cancer activity, stage and prognosis in 
gastric tumours (Chan and others 2006, Malle and others 2009). Recent 
immunohistochemical studies in people with oesophageal carcinoma suggest that tumour 
tissue may itself elaborate APP (Nozoe and others 2002) with a poorer survival and outcome 
associated with tumours that elaborated higher levels of CRP.  A similar association has 
been seen between AGP and colorectal tumours and ovarian carcinoma (Elg and others 
1997, Croce and others 2005).  
In veterinary patients, elevated levels of AGP have been identified in dogs with a range of 
tumours with AGP localisation to liver and splenic tissue in one study (Yuki and others 
2011).  Another study found higher levels of AGP in dogs with non-specific tumours of grade 
III-IV based on the WHO Tumour Node Metastasis (TNM) scale (Itoh and others 2009) and 
elevated serum AGP has been documented in non-specific tumour-bearing cats (Selting and 
others 2000) Elevated CRP levels have been documented in both dogs and cats with 
lymphoma (Tecles and others 2005, Mischke and others 2007) and serum CRP may be 
used as an indicator of complete remission status in dogs with multicentric lymphoma 
(Nielsen and others 2005).  Elevated levels of CRP, Hp and SAA have been identified in 
dogs with mammary tumours, with significant increases over normal being seen in the 
presence of metastatic disease, primary tumours greater than 5cm in diameter and those 
with ulceration (Planellas and others 2009, Tecles and others 2009).  
Because APPs are by their nature non-specific, with marked variation in their response to 
tissue damage and inflammation, measurement of several APPs in tandem is likely to be 
more useful than looking at a single value in isolation.  It has been suggested that APP 
profiles that use at least one major, one moderate and one negative APP may optimise 
clinical use (Ceron and others 2005).  For the purpose of this study we evaluated Serum 
Amyloid A (SAA), C-reactive protein (CRP), Haptoglobin (Hp), and Alpha 1-Acid 
Glycoprotein (AGP) in client-owned dogs referred for surgical and medical treatment of 
cutaneous mast cell tumours (MCT) and soft tissue sarcomas.  The results were then 
assessed to see whether specific increases within the profile were associated with the 
presence of the tumour and the grade. 
 
Materials and Methods 
Client-owned dogs referred to the authors’ institution for treatment of cutaneous MCTs 
(n=20) and sarcomas (n=21) were prospectively enrolled in the study.  Cases were only 
enrolled in the study if blood sampling formed part of the clinical investigation and/or 
treatment, and where residual blood was available after diagnostic sampling which would 
otherwise have been disposed of as clinical waste. Criteria for inclusion in the study were 
that the patient was not currently being treated with steroids, did not have a recent history of 
infectious or inflammatory disease other than the tumour, a definitive histological diagnosis 
was available for the tumour and a full staging procedure was completed prior to surgery 
using standard oncological protocols to identify metastatic disease where present.  Following 
surgical resection each tumour was submitted for full histological evaluation and grading to 
include assessment of the margins of excision.  MCTs were further divided based on the 
system described by Patnaik and others (1984); there were 5 tumours which met the criteria 
for grade 1 (the lowest grade) and 15 grade 2.  None met the criteria for grade 3 (the most 
severe grade).  A more recent system described by Kiupel and others (2010) classifies 
MCTs as either high grade or low grade; high-grade MCTs as those the presence of any one 
of the following criteria: at least 7 mitotic figures in 10 high-power fields (hpf); at least 3 
multinucleated (3 or more nuclei) cells in 10 hpf; at least 3 bizarre nuclei in 10 hpf; 
karyomegaly (ie, nuclear diameters of at least 10% of neoplastic cells vary by at least two-
fold). Fields with the highest mitotic activity or with the highest degree of anisokaryosis are 
used to assess the different parameters.  aAlthough this newer system has the advantage of 
greater simplicity it was not applied retrospectively to the cases in this study. 
The sarcoma group included soft tissue sarcoma (4), fibrosarcoma (2), haemangiosarcoma 
(5), chondrosarcoma (2), osteosarcoma (7), histiocytic sarcoma (1) and poorly differentiated 
sarcoma (2).  Although the variety in histological type in this group meant that a single 
grading system such as that proposed by Dennis and co-workers in 2010 for soft tissue 
sarcoma could not be used, each tumour was assigned a subjective grade by the pathologist 
who assessed the slides, based on well-established histological markers of malignancy such 
as mitotic index and degree of differentiation.  
Blood samples were collected from either the jugular vein or cephalic vein at the time of 
presentation and before any invasive procedures, and residual serum was stored temporarily 
at -4oC and then at -20oC degrees centigrade until assayed.  The APP levels were 
determined as previously described in detail by Lowrie and others (2009 a and b) as well as 
Eckersall and co-workers (1991, 1999).  In brief, the CRP levels were determined by 
immunoturbidometric assay and Hp by means of haemoglobin binding capacity assay. SAA 
was measured with a commercial canine ELISA kit (TriDelta Development, Dublin, Ireland) 
and AGP was measured with a commercial radial immunodiffusion assay (J-Path Inc, Tokyo, 
Japan).   
Normal values used by the laboratory for each APP that formed part of the profile were 
based on samples previously collected from healthy dogs (CRP n=51, HP n=54, SAA n=39, 
AGP n=37).   
 
Statistical analysis 
All comparisons using continuous data were checked for normality and equality of variances 
and appropriate statistical tests were employed.  In order to test the hypothesis that APP 
concentrations in dogs with MCT or sarcoma were significantly different from normal 
reference ranges for each APP, we calculated a student’s t test (operationalised as a two-
sample Welch’s test for samples of unequal sizes and variances) of whether the means of 
two independent, normally distributed populations were equal. 
In order to test the hypothesis that APP concentrations were significantly different in dogs 
with different grades of tumour Mann-Whitney tests were used. In order to test the 
hypothesis that dogs with APP concentrations above the normal reference range for each 
APP were associated with MCT or sarcoma grade Chi-square tests or Fishers exact tests 
were used, where appropriate.  
 
Results 
Hypothesis 1: APP concentrations in dogs with MCT or sarcoma are significantly different 
from the normal reference ranges for each APP (table 1.). 
CRP concentration was statistically significantly greater than reference range CRP in dogs 
with MCT (p-value <= 0.00) and sarcoma (p-value = 0.02). Hp concentration was 
significantly greater than reference range Hp in dogs with sarcoma (p-value <= 0.00), but not 
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those with MCT (p-value = 0.58).  Surprisingly, the SAA concentration was significantly lower 
than reference range SAA in dogs with MCT (p-value <= 0.00), but not significantly different 
from the normal reference range in dogs with sarcoma (p=0.22). The AGP concentration 
was significantly greater than reference range AGP in dogs with sarcoma (p-value < 0.00), 
and also with MCT (p-value = 0.02). 
 
Hypothesis 2:  APP concentrations are significantly different in dogs with different grades of 
MCT or sarcoma (table 2.). 
SAA concentration was statistically significantly greater in dogs with grade 2 sarcoma when 
compared to dogs with grade 1 sarcoma (p-value =0.02), however the SAA concentrations 
were not significantly higher than normal valuesreference ranges in either grade. There were 
no statistically significant differences in any of the other APPs when compared to tumour 
grade. although sample size was low which could have affected the findings or lack of 
statistical significance  
 
Hypothesis 3: Dogs with APP concentrations above the normal reference range for each 
APP are associated with MCT or sarcoma grade.  
None of the positive APPs were statistically significantly associated with sarcoma or MCT 
grade in dogs with elevated APP.  however the majority of grade 2 sarcoma cases fell into 
the positive category for CRP and Hp with values above the normal reference range (see 
Table 3) and both grade 1 and grade 2 sarcoma had more cases falling in the SAA negative 
group with values below the normal reference range.  
 
 
Discussion 
 
Patients with neoplastic disease often have altered immune status, such that a greater 
response than normal can be expected to challenges to the immune system (Duthie and 
others 1997, Kishi and others 1999). The proportion of T helper 2 cells that produce 
cytokines including interleukins 4, 6 and 10 are increased in tumour bearing patients and this 
suppresses cellular immunity (Blay and others 1993, Oka and others 1996, Berghella and 
1998).  Tumour cells will produce large amounts of active-type transforming growth factor 
beta, cytokines including interleukins 6 and 10, and prostaglandin E2, which again suppress 
cellular immunity (Takiuchi and others 1992, Oka and others 1994, 1995 and 1996, 
Berghella and others 1998). These alterations to immune status in patients with neoplastic 
disease and the resulting changes in the APP component of the inflammatory response are 
largely what underpin the potential use of APP profiles to assess tumour burden and 
prognosis (Itoh and others 2009).   
 
CRP was the first APP to be identified, and it is the major human APP (Eckersall and Bell 
2010).  Serum CRP has been identified as a useful prognostic factor in several clinical 
studies of colorectal neoplasia in humans (Nozoe and others 1998 and 2000, McMillan and 
others 2003, Canna and others 2004, Crozier and others 2006, Gunter and others 2006).  It 
was found to have the potential as an independent marker to predict early disease 
recurrence in stage I and II colorectal patients in one study, with the investigators concluding 
that it was superior to the carcinoembryonic antigen (CEA)-independent prognostic marker it 
was judged against (Koike and others 2008).  In patients with oesophageal squamous cell 
carcinoma CRP levels are prognostic for survival, particularly the level of CRP expression 
within tumour tissue (Nozoe and others 2002).  CRP may also be useful for prognosis in 
renal squamous cell carcinoma where it correlates with disease free interval (Casamassima 
and others 2005).  In men with androgen-independent prostatic cancer, elevated CRP levels 
are strongly predictive of poor survival (Beer and others 2008).  There are many known 
possible causes of elevated CRP in dogs, including babesiosis, leptospirosis, leishmaniasis, 
parvovirus and E.coli endotoxaemia arthritis, lymphoma and inflammatory bowel disease 
(Jergens and others 2003, Ceron and others 2005, Nielsen and others 2007, Lowrie and 
others 2009a); and a range of neoplastic diseases although specific correlations have only 
be described so far for mammary tumours and lymphoma (Mischke and others 2007, 
Planellas and others 2009, Tecles and others 2009,Yuki and others 2011).  Cases in the 
MCT group in our study had significantly elevated CRP levels compared to the normal range 
while cases in the sarcoma group had elevated levels of CRP, Hp and AGP.  Fujimoto and 
others (2003) documented previously that canine mast cell activation is linked to CRP with 
mast cell migration in response to CRP being both chemokinetic and chemotactic.  The 
authors postulated that CRP may play a role in migration of mast cells to areas of 
inflammation during the acute phase response.  One of the main biologic functions of CRP 
lies in its ability to identify damaged or abnormal cells, and then mediate their elimination 
through recruitment of complement and phagocytic cells.  Whether the elevated CRP in 
cases with MCTs reflects a response to neoplastic-induced inflammation, or potentially a role 
in tumorigenesis is unknown however it intuitively seems more likely that CRP is involved 
through the neoplasia-induced inflammatory response.  Large, rapidly growing tumours are 
more likely to contain areas of ischemia and/or to develop ulceration, both of which will incite 
a non-specific inflammatory response to tissue damage and tumour necrosis (Planellas and 
others 2009, Tecles and others 2009).   
 
It has been shown that human patients with advanced malignancies who have AGP 
glycoforms containing highly fucosylated triantennary and tetra-antennary sugar chains for 
long periods after surgery are likely to have a poor prognosis although there was no 
correlation with tumour size or metastatic disease (Hashimoto and others 2004).  These 
authors also documented in a previous study that levels of serum alpha (1,3)- 
fucosyltransferase, the enzyme response for fucosylation of AGP, is elevated in patients with 
highly malignant or metastatic disease and a separate study suggested that tumour tissue 
may itself be the source of this raise (Asao and others 2001).  There is currently little or no 
information available regarding AGP in dogs with neoplastic disease, and to the authors 
knowledge no studies have looked at the potential role of different glycoforms of AGP in 
dogs with tumours.  In our cases the AGP level was significantly different to normal in dogs 
with both MCT and sarcoma.  Our findings suggest that measuring AGP may be useful in 
dogs with these tumours, although the numbers were too small to evaluate whether there is 
a direct link with tumour size, grade and extent of disease. 
 
There is only one subtype of Hp known in dogs, compared to three in humans, and there are 
at least two identifiable structural differences between human and canine Hp.  Fucosylated 
Hp has been identified as a marker of disease in human pancreatic cancer and as a 
glioblastoma-specific serum marker and expression of haptoglobin has been found to predict 
recurrence in human head and neck cancer (Ching-Chih and others 2010, Kumar and others 
2010, Miyoshi and others 2010). Glycosylation patterns are known to vary between different 
disease states in dogs (Andersson and others 1998) and a study by Andersson and Sivelius 
in 2001 identified a higher incidence of Hp glycosylation in both auto-immune disease and 
neoplasia of lymphoreticular or myeloproliferative origin.  There are numerous studies 
documenting elevated Hp in cattle, pigs, sheep and horses with non-neoplastic diseases 
such as babesiosis and mastitis, but very little information regarding Hp in small animal 
populations, and in particular very little regarding Hp in specific neoplastic conditions.  To the 
authors knowledge this is the first study looking at Hp levels in dogs with solid tumours of 
soft tissue origin.  Similar to the findings for AGP, we found that Hp levels were elevated in 
dogs with sarcoma but not in those with MCT.  Interestingly, Hp has been shown to bind to 
human mast cell line HMC-1, inhibiting up to 40% of the spontaneous growth of the cells (El-
Ghmati and others 2002).  Whether this is related to the findings here that there is no 
increase in Hp in dogs with MCT is an intriguing question and worthy of further study. 
 
SAA has been shown to increase in a wide range of human malignancies, including gastric, 
nasopharyngeal, colorectal and breast cancer, as well as in mouse models for cancer 
research (Biran and others 1986, Chan and others 2006).  Gutfeld and co-workers (2006) 
investigated the expression of SAA at various stages of human colon carcinoma progression 
and found that expression increased gradually as cell progressed through dysplasia to 
neoplasia. RT-PCR analysis confirmed the expression of the SAA1 and SAA4 genes in 
colon carcinomas, expression that was barely detectable in normal colon tissues.  These 
findings led the authors to postulate that SAA production may play a role in colonic 
tumorigenesis.   A role in cancer progression has been suggested as a result of the apparent 
relationship between SAA levels and development of metastatic disease from solid tumours 
(Ramankulov and others 2008).  Elevation of this APP in dogs with known malignancy would 
seem logical; however this was not what we found.  Interestingly, and unexpectedly, the SAA 
levels in dogs with MCT were significantly lower than the reference range, but those patients 
with sarcomas had no significant difference when compared with the normal range.  Sample 
size was low however which could have affected the findings or lack of statistical 
significance  
It is difficult to explain this apparent reversal of what would normally be expected with a 
major APP in the presence of neoplastic disease.  SAA is not affected by the presence of 
haemolysis, lipaemia or bilirubinaemia in blood samples; it is not influenced by sex or age, 
and is not prone to significant circadian variations (Ceron and others 2005).   
 
Conclusions: 
The numbers in our groups were small which compromises the validity of statistical 
evaluation so our results must be interpreted with caution.  However some interesting 
relationships have emerged from the initial evaluation. Our findings suggest that specific 
combinations of serum APPs for MCTs and sarcomas may be useful as a screening test for 
the presence of disease.  For patients with MCTs, CRP and AGP levels would be expected 
to increase, with a concurrent drop in SAA levels.  In sarcoma patients CRP, AGP and Hp 
can all be expected to increase.  These initial results need to be evaluated in larger numbers 
of cases with naturally occurring disease to validate the findings.  Further areas for 
investigation include assessment of correlation between APP levels and presence of 
metastatic disease, and whether the APP values alter following surgery as has been 
documented in people.   
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Table 1. APP values for MCT and SARCOMA compared to a “normal” control group (i.e. 
normal range) using two-tailed P-values i.e. alternative hypothesis is that mean APP values 
for affected individuals are significantly different from those of normal intervals (significance 
set at p<0.05) 
APP Normal 
mean (SD) 
MCT mean 
(SD) 
N= 20 
Two-sample 
T-test  
p-value 
SARCOMA 
mean (SD) 
N=21 
Two-sample 
T-test  
p-value 
CRP 1.97 (1.34) 10.41 (7.43) <0.00 26.21 (42.01) 0.02 
HAPTO 1.59 (0.57) 1.83 (1.90) 0.58 2.99 (1.77) <0.00 
SAA 2.88 (0.34) 1.67 (1.34) <0.00 6.06 (11.10) 0.22 
AGP 0.26 (0.11) 0.53 (0.45) 0.02 0.65 (0.26) <0.00 
 
Table 2. Mann-Whitney tests for comparison of the APP values obtained and the grade of 
the MCT or Sarcoma  (significance set at p<0.05)  
APP 
MCT grade 
1 (median)  
N=5 
MCT grade 
2 (median) 
N=15 
Mann-Whitney 
p-value 
Sarcoma 
grade 1 
(median) 
N=7 
Sarcoma 
grade 2 
(median)  
N=14 
Mann-Whitney 
p-value 
CRP 9.91 12.49 0.97 9.21 13.28 0.14 
HAPTO 2.39 0.90 0.24 1.68 3.27 0.08 
SAA 1.06 1.47 0.63 0.80 2.04 0.02 
AGP 0.69 0.31 0.32 0.45 0.68 0.74 
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